{'fraction_non_alphanumeric': 0.030694591219137285, 'fraction_numerical': 0.018541646651935823, 'mean_word_length': 4.984190859442369, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing

Background Clinical complications of long-term anticoagulation in patients with atrial fibrillation cause significant morbidity and have a substantial economic impact on the healthcare system. Objective To assess the cost-benefit by implementing patient self-testing (PST) in German patients anticoagulated with vitamin K antagonists (VKA) compared to treatment with the new oral anticoagulant drugs (NOAC) apixaban, dabigatran, edoxaban, and rivaroxaban. Methods A deterministic decision-analytic model was developed simulating the number of major bleedings, ischemic strokes, and hemorrhagic strokes and their associated costs by utilizing PST compared to those of treatment with NOAC. Data on the rates of these adverse events in both groups during the 1st year of treatment was taken from the NOAC approval studies. Direct costs were evaluated from the perspective of the Statutory Health Insurance (SHI) considering the use of resources directly related to PST testing and costs incurred by hospital treatment of the adverse events. Univariate sensitivity analysis was performed to examine the extent to which our calculations were affected by varying the parameters considered in our model within plausible extremes. To capture the interactions between multiple inputs, we also provided a probabilistic sensitivity analysis (PSA). Results When achieving an average time in therapeutic range (TTR) of 78%, implementing PST in VKA patients reduces cost per patient compared to NOAC treatment between €603.38 [USD 681.52] (edoxaban) and €762.64 [USD 861.40] (rivaroxaban) during the 1-year observation period. In line with the TTR increase, the initially higher number of adverse events per VKA patient compared to NOACtreated patients in the approval studies becomes largely aligned; the difference in associated hospital costs per patient in the NOAC groups is then only €1.03 [USD 1.16] (in favor of dabigatran), €23.41 [USD 26.44] (in favor of apixaban), €0.53 [USD 0.60] (in favor of edoxaban) and €52.62 [USD 59.43] (in favor of VKA anticoagulation in the rivaroxaban group). In PSA, implementation of self-management results on average in a cost saving between €619.20 [USD 699.39] and €785.24 [USD 886.93] per VKA patient in favor of the SHI. Under all reasonable assumptions, PST remains constantly less expensive irrespective of which NOAC is administered. Conclusion Implementing PST in German VKA patients may significantly reduce SHI expenditures compared to utilizing NOAC.


INTRODUCTION
Atrial fibrillation (AF) increases the risk of stroke by a factor of 4-5 and accounts for almost 15% of all ischemic strokes. 1 One in four middle-aged adults in Europe and the US is expected to develop AF, and by 2030, up to 7 million AF patients are anticipated in the European Union. 2 Several studies have demonstrated that the risk of stroke is reduced by oral anticoagulant therapy with vitamin K antagonists (VKA), especially warfarin and phenprocoumon, which were the only oral anticoagulants available until a few years ago for primary and secondary prevention of thromboembolic events.
Currently, the non-vitamin K oral anticoagulants (NOAC) dabigatran, rivaroxaban, apixaban, and edoxaban are approved as potential alternatives of VKA treatment. [3][4][5][6][7] As some metaanalyses suggest superiority of NOAC treatment versus VKA with respect to reduction of thromboembolisms and bleeding complications, the use of NOAC is recommended in the 2016 European Society of Cardiology (ESC) guidelines as first line therapy for anticoagulation in atrial fibrillation. 1 However, one major point of criticism as stated by the Drug Commission of the German Medical Association 8 is the unexpected short mean "time in therapeutic range" (TTR) of the International Normalized Ratio (INR), a standardized value to measure the required prolongation of prothrombin time, in the warfarin control groups of all NOAC approval studies. [3][4][5][6][7] Thus, the higher rates of adverse vascular events in VKA patients investigated in those studies may partly be explained by the low mean TTR ranging between 55% (rivaroxaban) and 66% (edoxaban). In contrast, those VKA patients who utilize patient self-management (PST) during their VKA treatment usually have a significantly higher TTR of about 78%. 9 In a cohort study of German AF patients using claim data of the most representative German SHI, the "Allgemeine Ortskrankenkassen" (AOK Health Insurance Fund) NOAC exposure was associated with significantly higher incidence rate ratios for death or non-specified strokes, myocardial infarction and severe bleeding suggesting that NOAC therapy doesn't seem to be more effective and safer than a VKA therapy in "real life." 10 In a recently published Danish study 11 on the treatment of AF patients, self-managed VKA treatment was associated with a significantly lower risk of all-cause and ischemic strokes compared to treatment with NOAC, whereas no significant differences were observed for major bleeding and mortality.
Indeed, there is evidence [12][13][14] that an increase of TTR in patients under VKA therapy by patient selftesting (PST) is associated with a lower frequency of the most severe three adverse events, namely ischemic and hemorrhagic stroke and major bleedings. Based on a large database of 67 077 Veterans Health Administration patients anticoagulated with VKA, Rose et al. 15 simulated the number of adverse events and their associated costs and utilities, both before and after various degrees of improvement in percent time in TTR, following a 2-year time horizon. There was demonstrated improvement in TTR by 10% with a prevented 2087 events, gained 1606 quality-adjusted life-years, and saved $29.7 million from the payer's perspective.
Derived from Rose's approach we defined mathematical formulas that allowed us to simulate the effects on the number of adverse events in the warfarin control groups of the original NOAC approval studies. We calculated the number of events that occurred when the original TTR in the studies would now uniformly increase to a mean TTR of 78% 9 ; a figure which has been shown to reflect the reality in PST.
In a second step we assessed the costs of NOAC and VKA treatment of AF patients when PST 16 was implemented for the first year under country specific conditions from the perspective of the German SHI.
Our aim was to examine the possible economic advantages of implementing PST in VKA patients compared to administering NOAC, when supervised by a properly trained general practitioner (GP). Since in Germany the short-acting warfarin is only rarely prescribed replaced it in our model of long-acting phenprocoumon, which is consumed by 98% of the German VKA patients 17 and allows a higher stability of plasma concentrations. 18

ETHICAL CONSIDERATIONS
Ethical approval was not necessary as only publicly available secondary data were used.

A) MODEL APPROACH
Our model was parametrized by data on the rates per patient and year of three main adverse events in the study populations of the four NOAC approval publications.
We assume that a relevant increase in the TTR is possible by PST under the supervision of a GP. Only costs to be carried by the SHI that arise on the legal basis of the German social security statute book (SGB) V are included. These are the costs of medication (NOAC and phenprocoumon), aids (CoaguChek ® system, test strips and lancets, see 16 in accordance with §31 SGB V), costs of training on the proper use of the test system, the costs for outpatient primary care and laboratory costs and the result of hospital stays as a result of adverse events. The frequency of the three adverse events in both comparison groups (patients with NOAC or VKA) reported in the NOAC approval studies 3-7 is standardized to one year due to the different duration of the approval studies in order to allow for comparability. Due to the lack of empirical data, the model assumes that the adverse events occur at the end of the first year of comparison and, due to their severity, require hospitalization.
The outpatient costs refer to the National Association of Statutory Health Insurance Physicians' Uniform Assessment JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH Standard (EBM), 19 as of January 2019 and -with respect to the reimbursement of medical devices and other aids for performing patient self-management -to the agreement with the National Association of Statutory Health Insurance Funds ("Spitzenverbände der Krankenkassen") of February 2002. Costs arising from hospitalization and from prescribing anticoagulants are based on the GDRG (German diagnosis related groups) system in the most recent version (2019) and the Pharmacy Sales Prices (Red List [Rote Liste ® ] 2019), respectively. Any discounts granted by the manufacturers of NOAC to some insurances are not taken into account for reasons of transparency.

B) MODEL STRUCTURE
A deterministic, patient-based decision-analytic model was developed, simulating the incremental costs of using one of the NOAC, compared to conventional VKA treatment, with and without PST. The perspective taken is that of the SHI itself (see Figure 1 for an example using apixaban). In this figure, the decision tree simulates the direct costs of the two alternative anticoagulation strategies per patient until the end of the first year for one year. We used TreeAge Software (TreeAge Inc. Williamstown MA, USA) for model building and analysis and examined our inputs over a wide range in sensitivity analyses to identify influential factors that would alter the base-case findings.
Univariate sensitivity analysis was performed using all variables to examine the extent to which our calculations are affected by varying selected assumptions. Variation was done using either a) the lower and upper bounds of the parameter if present or b) the lower and upper bounds of a parameter's 95% confidence interval. Where this is not applicable, we vary parameter values by ± 20% of the base-case value according to international practice, unless stated otherwise.
Furthermore, in order to capture the interactions between multiple inputs we provide a probabilistic sensitivity analyses (PSA) by assigning an appropriate statistical (probability) distribution to all input parameters, from which values are randomly drawn in a 2nd order Monte-Carlo simulation (n=1000 Input parameters are shown together with their probabilistic distributions in Table 1.

MATHEMATICAL MODEL
The information from Table 5 of Rose's publication 15 was utilized to calibrate a model that captures the influence of a change (delta, Δ) in TTR (ΔTTR) on the number of ischemic strokes (IS) and major hemorrhages (MH) in relationship to those TTR changes. As MH and hemorrhagic strokes (HS) were not assessed separately in Rose's publication we assumed that the effect of TTR increase on MH and HS would be the same.
We standardized the data fromRose et al. 15 to derive a linear dependency structure in a regression framework. Subsequently, we regressed TTR on IS and TTR on MS to derive a dependency structure using robust standard errors, where regression results are reported in Table 2.
The estimated coefficients were used to generalize the findings of Rose et al., i.e., we utilize the following relationship to estimate mean relative savings: Relative Savings in IS = 0.0134 + 0.6754 * ΔTTR and Relative Savings in MH = 0.0101 + 1.4282 * ΔTTR Multiplying the relative savings in IS or relative savings in MH, resulting from a particular ΔTTR, with the baseline IS or MH defines the savings in IS and MH related to a particular ΔTTR.
To incorporate and compare results from different studies we standardize effects to a patient at risk in the respective study population using the following relationship: Saving IS: Baseline of study (number per study patient at risk in % per year) * (0.0134 + 0.6754 * ΔTTR) Saving MH: Baseline of study (number per study patient at risk in % per year) * (0.0101 + 1.4282 * ΔTTR).

EPIDEMIOLOGICAL PARAMETERS (TAKEN FORM THE APPROVAL STUDIES 3-7)
The risk of having an ischemic stroke (IS), hemorrhagic stroke (HS) or major bleedings (MB) in the NOAC approval studies are separately shown for the respective NOAC and the warfarin control group in Table 3, together with the mean time in therapeutic range (TTR) of the warfarin group members. ***, **, * indicates significant estimates at the 0.01, 0.05, and 0.1 significance level with T-statistics in parentheses

Cost of coagulation self-management
The measurement intervals for coagulation selfmanagement are much closer than for measurements exclusively in primary care practice (see below). An autonomous self-adaptation of the phenprocoumon dose requires training, a sufficient stock of test strips and the presence of a (maintenance-free) test device.  1.6.2019). The CoaguChek®-INR device is depreciated over 60 months, as is customary for medical measuring instruments (36 months to 10 years in sensitivity analysis).

Laboratory costs in the GP's practice
According to the statements in the Federal Gazette, a total of 6 additional medical check-ups are accepted in medical practice (1st quarter in each case monthly, i.e., three times, and one time each in the 2nd up to the 4th quarter. As it is also necessary to check to what extent the INR value obtained with the CoaguChek ® INR system is in accordance with the laboratory value as a reference, it is generally assumed that the blood will be drawn at the GP's practice and subsequently transferred to the collaborative laboratory. The laboratory community will receive €0. 6

Cost of NOAC control
According to the proposals of the 2nd edition of the Practical Guide of the European Heart Rhythm Association 23 follow-up intervals are required for NOAC: first check one month after the initial prescription; in addition, then clinical controls ± every 3 months, a maximum of 6 months depending on patient factors such as age, renal function and comorbidities.
Nevertheless, in view of the frequent comorbidities in patients with AF, e.g. diabetes mellitus or arterial hypertensions, it would be unrealistic to assume that during the study period of one year NOAC patients would not see their doctor for whole quarters and that type and frequency of routine parameters to be investigated (blood count, liver and kidney values) differ from those of phenprocoumon patients. Therefore, the same costs, as for VKA patients, of €113.40 [USD 128.09] are assumed as payment for the GP per year. The costs for determining those routine parameters are not calculated separately for reasons of insignificance (determining the creatinine value, for example, amounts to only €0.25 [USD 0.28] and performing a blood count to only €0.5 [USD 0.56]) and are not considered in our model.

RESULTS
Achieving a mean TTR of 78% by implementing patient's self-management (PST) is on average between €603.38 [USD 681.52] and €762.63 [USD 861.39] less costly in the first year per VKA patient, compared to utilizing NOAC (see Table 4 a-b). Assuming that an increase of the original mean TTR as reported in the respective approval studies by approximately 16 percentage points for apixaban, 14 points for Dabigatran, 13 points for edoxaban, and 23 points for rivaroxaban to the target of 78% can be achieved, the number of severe adverse events in VKA patients decreases, and accordingly the associated hospital costs become largely aligned. Thus, after TTR adjustment, the cost difference for those severe events per VKA and NOAC patient in the various groups is then only €1.  In contrast, varying the G-DRG costs of hospitalization for treating the ischemic or hemorrhagic stroke or major bleeding as potential adverse events by ± 20% resulted in minor changes of total cost. This is because costs incurred for those adverse events would always change in parallel in both arms of the decision tree.
In PSA, i.e. under all reasonable assumptions, the costs of implementing PST for anticoagulation at the expense of the SHI saved on average was between €619.2 [USD 699.39] (edoxaban) and €785.24 [USD 886.93] (rivaroxaban, see Table  5). Here treatment with phenprocoumon remains constantly less expensive than treatment with one of the four NOAC.     In contrast, the risk per patient of suffering from one of the three severe adverse events (ischemic or hemorrhagic stroke or major bleeding) under VKA or NOAC is in fact only in the single-digit percent level or lower.
Increasing the TTR from the respective mean baseline level of the VKA population in the approval studies (starting from a TTR of 55%, 63% or 65%) to 78%, the realistic target of our model, nearly outweighs the initially lower number of strokes and bleedings in NOAC patients. Accordingly, the remaining differences in the associated costs compared to those incurring for severe advents in the respective NOAC groups are low. Therefore, although the costs of implementing PST, especially the costs of the INR measurement device and the patient mandatory training, in VKA patients are not negligible, NOAC drug costs remain the high cost component in our costbenefit analysis.
Probabilistic sensitivity analysis (PSA) that considers realistic assumptions of uncertainty, demonstrates that performing PST is consistently less expensive than a NOAC. Thus, even when comprehensive discount agreements on the pharmacy retails between NOAC manufacturers and individual health insurance organizations are taken into consideration, self-managed VKA treatment can be considered the strategy of choice as far as economic aspects in favor of the German SHI are concerned.
Our study has some limitations that must beconsidered when interpreting our results: First, the effects of TTR increases on the number of adverse events and their associated costs are based on a mathematical approach that has been derived from a previous U.S. study without a direct relationship to the NOAC approval studies.
Second, in all NOAC approval studies warfarin was used as VKA, however, is rarely prescribed in Germany in favor of phenprocoumon. Thus, in our analysis we set warfarin and phenprocoumon, that have identical costs per tablet in Germany, to the same level of adverse effects reported in the NOAC approval studies. We should note our model may overestimate the warfarin-induced adverse effects as reported in the respective approval studies. This is because warfarin has a shorter half-life than phenprocoumon, that patients using phenprocoumon have more often INR values in therapeutic range than warfarin and thus phenprocoumon seems preferable for use in long-term therapeutic anticoagulation. 24 Third, our calculations refer only to the treatment of strokes and major bleedings immediately after diagnosis in a German hospital. Excluded from the model are costs for aftercare services provided by special rehabilitation centers, or physiotherapeutical services offered in ambulatory outpatient settings.
Fourth, the results of the model can only be generalized if all VKA patients are mentally able to participate in PST and are willing to perform the ongoing INR checks, and that all NOAC patients regularly take their drug in the suggested doses. Indeed, a 100% implementation of PST for all patients who actually are anticoagulated with vitamin K antagonist may be a quite unrealistic option. However, in a large prospective cohort study in Switzerland those patients who decided to participate in PST had a high adherence of about 90% during a median followup of 4.3 years. 25 On the other hand, there are concerns whether the results of the double-blinded approval studies of the four NOAC under consideration can also be assumed to be valid in real life: For example, in US-Veterans the adherence of AF patients to Dabigatran was reported to be only 72.2%. 26 As the risk of a 156 Diel R, et al.

JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH
stroke increases by 13% per 10% less adherences (HR 1.13; 95% CI 1.07-1.19), an advantage with respect to adverse events simply by administering NOAC is not guaranteed. 27,28 Thus, to validate our estimates, more cost studies, preferably with a multicenter and prospective study design, are required.

CONCLUSION
The utilization of PST in anticoagulated German VKA patients with atrial fibrillation is likely to reduce overall costs. As such, routine implementation of PST may have also direct and positive impact on the control of clinical complications, especially stroke and major bleeding rates. Prospective clinical studies should be undertaken to prove our model and to further evaluate its economic advantages in the immediate future.